Maze Therapeutics

Biotech

mazetx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
40
4 granted · 36 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1300TOMEGAVAX, INC.——
1301Windward Bio——
1302Azalea Therapeutics——
1303Maze Therapeutics——
1304LUNG THERAPEUTICS INC——
1305Immunomedics——
1306INVENIO THERAPEUTICS INC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 4 granted of 40
  • Inhibitors Of Glycogen Synthase 1 (GYS1) And Methods Of Use Thereofapplication
  • Inhibitors Of Solute Carrier Family 6A Member 19 (SLC6A19) And Methods Of Use Thereofapplication
  • Inhibitors Of Solute Carrier Family 6A Member 19 (SLC6A19) And Methods Of Use Thereofapplication
  • Dimeric Compounds As Inhibitors Of Glycogen Synthase 1 (GYS1) And Methods Of Use Thereofapplication
  • N-(benzhydryl)cycloalkylcarboxamide Derivatives As Inhibitors Of Glycogen Synthase 1 (GYS1) And Methods Of Use Thereofapplication
  • APOL1 Inhibitors And Methods Of Useapplication
  • Inhibitors Of Glycogen Synthase 1 (GYS1) And Methods Of Use Thereofgranted
  • Cycloalkyl Carboxylic Acid Derivatives As Inhibitors Of Glycogen Synthase 1 (GYS1) And Methods Of Use Thereofapplication
  • APOL1 Inhibitors And Methods Of Uses Thereofapplication
  • APOL1 Inhibitors And Methods Of Useapplication
  • APOL1 Inhibitors And Methods Of Usegranted
  • Compositions And Methods For Treating TDP-43 Proteinopathyapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.